We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Innovative researchers working to tackle some of the hardest-to-treat cancers, including through the use of AI, have received a £2 million funding boost.
For the first time, patients with certain types of advanced or recurrent endometrial cancer could access a treatment shown to slow its progression
Patients with a certain type of advanced or spreading non-small cell lung cancer (NSCLC) could access a new cancer therapy to help treat their condition.
Ground-breaking new cancer treatments have moved a step closer with the signing of a major agreement between the government and BioNTech SE.
A report on whether appropriate assessment of older cancer patients would result in better access to cancer treatment.
Government bringing together experts in the field to drive forward progress in tackling cancer in children and young people.
Millions invested in eight innovative companies behind lifesaving new medical technology which could destroy liver cancer tumours, detect Alzheimer’s and quickly spot those at risk of stroke
EAMS scientific opinion issued to GlaxoSmithKline UK Limited for dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates...
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
Information and sources of further guidance relating to the current shortage of products used in the treatment of some bladder cancers
We inform healthcare professionals of new risk minimisation measures for JAK inhibitors used to treat chronic inflammatory disorders, consistent with the measures introduced for tofacitinib (Xeljanz) in 2020 and 2021. This advice affects abrocitinib (Cibinqo▼), baricitinib (Olumiant), upadacitinib (Rinvoq▼), and...
Population-based statistics on cancers treated with chemotherapy, radiotherapy and surgical tumour resection which were diagnosed between 2013 and 2016 in England.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
Information on the waiting times of patients with suspected cancer and those subsequently diagnosed with cancer. Information on the number of people who attended outpatient appointments within two weeks of an urgent referral by their GP for suspected cancer or...
Projects granted during 2015 that have a primary purpose of basic research: oncology.
£21 million is being allocated to 64 NHS trusts across England to roll out AI tools to speed up the diagnosis and treatment of lung cancer.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.